Evidence map›Paper›PMID 39764929›Full record

ArticleDrug and alcohol dependence2025

Bariatric surgery and alcohol and substance use: A case-control survey study.

Shannon N Speed, Garrick T Sherman, Tammy Wang, Claire L Pince, Jenna E Sanfilippo, Chiara Montemitro, Salvatore Giorgi, Brenda L Curtis, Lisa A Farinelli, Mehdi Farokhnia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shannon N SpeedClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA.
Garrick T ShermanOffice of the Clinical Director, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Tammy WangClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA.
Claire L PinceClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA.
Jenna E SanfilippoClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA.
Chiara MontemitroCenter for Social and Affective Neuroscience. Linköping University, Linköping, Sweden.
Salvatore GiorgiTechnology and Translational Research Unit, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Brenda L CurtisTechnology and Translational Research Unit, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Lisa A FarinelliClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA.
Mehdi FarokhniaClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA.
Lorenzo LeggioClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, Baltimore, MD, USA. Electronic address: lorenzo.leggio@nih.gov.

Funding

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIADA000635 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI LEGGIO, LORENZO · 2020 to 2025
$15.2M
Intramural NIH HHS ZIA DA000635
6 · The paper itself

Abstract

purposeStudies suggest alcohol and/or other substance misuse may develop after bariatric surgery (BS), but findings are not consistent or conclusive. PROCEDURES: This cross-sectional online survey investigated alcohol and other substance use, via a modified version of the Alcohol Use Disorders Identification Test, before and after bariatric surgery, compared to a non-bariatric surgery sample. Data were anonymously collected via Qualtrics from adults who reported alcohol or substance use (BS, n = 328; non-BS, n = 292).

findingsProblematic alcohol, opioid, amphetamine, and cannabis use were reduced post-surgery compared to pre-surgery. After surgery, participants expressed "guilt" associated with alcohol and other substance use (average 0.24 and 0.31 points higher, respectively) compared to pre-surgery. Compared to controls, the bariatric surgery group reported on average 1.99 points less problematic nicotine use pre-surgery (p = .012) and 2.42 points less post-surgery (p = .004). In contrast, compared to people without any history of bariatric surgery, the bariatric surgery group reported greater problematic use of alcohol, cannabis, hallucinogens, and/or inhalants pre-surgery (all p < .001); same results were found post-surgery for all drugs, (all p < .001) except for hallucinogens which was not significantly different between the two groups. RELEVANCE: Unlike previous reports, these survey-based results do not show an increase in problematic alcohol and substance use following bariatric surgery. Recall biases and the survey-based methodology are however important limitations of the present study. The observed increase in "guilt" associated with substance use may align with growing evidence suggesting increased subjective response to alcohol and other substances following bariatric surgery.

Indexed as

Alcohol DrinkingAlcoholismBariatric SurgerySubstance-Related DisordersAdultCase-Control StudiesCross-Sectional StudiesFemaleHumansMaleMiddle AgedSurveys and QuestionnairesYoung AdultAlcoholBariatric surgeryGut-brain axisSubstance

Identifiers

PMID39764929
PMCPMC11780309

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.